Company news
Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A (SSE:603707) news
Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, May 24, 2025: Announcement on Not Revising Downward Conversion…
View Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A →
Press releases — page 2
Announcement on Not Revising Downward Conversion Price of "King-friend Convertible Bonds"
May 23, 2025
Announcement on Obtaining Loan Support for A-share Repurchase Funds
May 22, 2025
Announcement on Resolution of the 2024 Annual General Meeting
May 20, 2025
Announcement on Subsidiary Obtaining the Registration Approval Letter for Drug Production Site Transfer of Idarubicin Hydrochloride Injection from FDA of the United States
May 19, 2025
Indicative Announcement on the Expected Fulfillment of Conversion Price Amendment Conditions for "King-Friend Convertible Bonds"
May 16, 2025
Announcement on Shareholding of Top 10 Shareholders and Top 10 Holders of Shares Without Sales Limit Concerning Shares Repurchase
May 15, 2025
Announcement on Convening 2024 Annual and Q1 2025 Performance and 2024 Cash Dividend Briefing
May 9, 2025
Announcement on Subsidiary Obtaining the Registration Approval Letter for Drug Production Site Transfer of Mitoxantrone Injection from FDA of the United States
April 29, 2025
Announcement on Changes in Accounting Policies
April 28, 2025